Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema

Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema. A National Registry.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00700934

Enrollment

300

Registered

2008-06-19

Start date

2005-02-28

Completion date

2012-02-29

Last updated

2010-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alpha 1-Antitrypsin Deficiency, Emphysema

Keywords

FEV1, mortality, Quality of life

Brief summary

The aim of this study is to describe the natural history of patients with alpha-1 antitrypsin associated emphysema and to figure out associated prognostic factors.

Detailed description

All patients who suffer from this disease are followed every 6 months during a 5 years period. FEV1 decline is the primary endpoint. Quality of life assessed using the Saint George's Respiratory Questionary is recorded too.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Serum alpha one antitrypsin \< 0.8 g/l * Emphysema diagnosed by CT scan * Adult * Obstructive disorder

Exclusion criteria

* Liver or lung transplantation

Countries

France

Contacts

Primary ContactGabriel Thabut, MD

g.thabut@bch.aphp.fr1 40 87 57 12

Outcome results